36X.F ASCENTAGE PHARM. DL-0001
- Market cap
- EUR 1.20B
- P/E
- -
- P/B
- 16.99x
- ROE
- -93.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 36X.F undervalued?
Graham numberThe Graham number of ASCENTAGE PHARM. DL-0001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ASCENTAGE PHARM. DL-0001 fundamental analysis
No fundamental analysis for ASCENTAGE PHARM. DL-0001 yet.
ASCENTAGE PHARM. DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ASCENTAGE PHARM. DL-0001
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecul…
Full company profileASCENTAGE PHARM. DL-0001 financial statements
ASCENTAGE PHARM. DL-0001 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 27.9M | 210M | 222M | 981M | 574M |
| Gross Profit | 24.6M | 188M | 191M | 952M | 525M |
| Operating Income | -870M | -850M | -873M | -370M | -1.20B |
| EBITDA | - | -771M | -744M | -238M | -1.10B |
| Net Income | -782M | -883M | -926M | -405M | -1.24B |
| EPS | -2.98 | -3.33 | -3.19 | -1.29 | -3.33 |
| Balance Sheet | |||||
| Total Assets | 2.94B | 2.83B | 2.50B | 2.62B | 3.96B |
| Total Liabilities | 1.71B | 2.42B | 2.43B | 2.34B | 2.63B |
| Shareholders' Equity | 1.23B | 409M | 60.4M | 264M | 1.32B |
| Cash & Short-term Investments | 1.71B | 1.48B | 1.07B | 1.24B | 2.46B |
| Cash Flow | |||||
| Operating Cash Flow | -605M | -654M | -726M | -111M | -1.17B |
| Capital Expenditure | 437M | 237M | 56.8M | 24.3M | 27.6M |
| Free Cash Flow | -1.04B | -891M | -783M | -136M | -1.20B |
| Ratios | |||||
| ROE | -63.4% | -216.1% | -1,532.1% | -153.5% | -93.8% |
| ROA | -26.6% | -31.2% | -37.0% | -15.5% | -31.4% |
| Net Profit Margin | -2,803.4% | -421.0% | -417.0% | -41.3% | -216.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ASCENTAGE PHARM. DL-0001 dividends
ASCENTAGE PHARM. DL-0001 has not paid dividends in the last 5 fiscal years.
Who owns ASCENTAGE PHARM. DL-0001
- Insiders 22.49%
- Institutions 17.57%
- Public & others 59.94%
- Shares outstanding 374M
- Free float 286M
ASCENTAGE PHARM. DL-0001 company profile
- Company name
- ASCENTAGE PHARM. DL-0001
- Ticker
- 36X.F
- ISIN
- KYG0519B1023
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 828
- Fiscal year end
- December
- Address
- Suzhou Industrial Park, Suzhou, China, 215000
- Phone
- 86 512 8555 7777
- Website
- ascentage.cn
About ASCENTAGE PHARM. DL-0001
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
ASCENTAGE PHARM. DL-0001 management
10- Dr. Dajun Yang M.D., Ph.D.Co-Founder, Chairman & CEO · born 1963
- Dr. Shaomeng Wang Ph.D.Co-Founder, Chief Scientific Advisor & Non-Executive Director · born 1965
- Dr. Ming Guo Ph.D.Co-Founder · born 1958
- Dr. Veet MisraChief Financial Officer
- Yuly ChenSenior Director of Investor Relations
- Mr. Thomas Joseph Knapp J.D.Senior VP & General Counsel · born 1953
- Dr. Yifan Zhai M.D., Ph.D.Chief Medical Officer · born 1963
- Dr. Chongdong FuSenior VP & Head of CMC
- Mr. Jin CaoHead of Finance · born 1986
- Mr. James Ziegler M.B.A.Chief Commercial Officer · born 1966